Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
00:10:34 Jennifer Clements If were treating obesity, we know that we have to address stigma and bias
Other studies have shown similar patterns
L.MetzlerM.McCutcheonK.ZhangT.et al (1998)
2013;11:e1001571
Length: 1/4 inch to 1/2 inch (6mm to 12.7mm)
US$ 22.09
US$ 24.53
US$ 27.01
US$ 26.35
US$ 24.40
US$ 22.12
US$ 22.01
